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12A ABSTRACTS - Angiography & Interventional Cardiology 
Methods: A novel dual-sensor guide wire (Doppler flow and pressure) was used in 12 
patients with a single de nova lesion to simultaneously measure distal coronary pressure 
(Pd) and flow velocity (v), as well as aortlc pressure (Pa) after an i.c. bolus of adenosine. 
At maximal hyperemia, SRv and MRv were calculated as (Pa - Pd) / v and Pd / v, 
respectively. The results were compared before treatment and after balloon dilatation, 
stenting and upsized stenting guided by intravascular ultrasound. The relative contribu- 
tion of the decrease in SRv to the gain in flow velocity after PCI was estimated using the 
pre-PCI value of MRv. 
Results: Hyperemic SRv decreased from 2.1i2.2 CRU pre-PCI (1 CRU = 1 mm Hg/cm/ 
set) to 0.21+0.21 CRU (p = 0.01) due to PCI. Hyperemic MRv changed from 2.5+1.3 
CRU to 1.5iO.32 CRU (p = 0.02) after PCI. Compared to the pre-PCI level, the cumula- 
tive increase in hyperemic flow velocity was 146*163 %. 66.4*61.6 %, and 22.6i112.7 
% after each respective PCI step. The average relative contribution of the reduction in 
SRv to this gain in flow velocity was 46.6*44.9%. Conclusion: Dilation of the epicardial 
coronary lesion by PCI results in a significant reduction in stenosis resistance and a 
marked decrease in hyperemic coronary microvascular resistance, which accounts for 
about half of the resulting gain in hypetemlc flow velocity. These data suggest that dila- 
tion of the epicardial stenosis has a marked effect on coronary perfusion also through the 
accessory reduction of microvascular resistance. 
1197-192 Influence of Diabetic Treatment Status on Survival After 
Successful Percutaneous Coronary Intervention 
Verahese Mathew. Robert L. Frye, Ryan Lennon, Gregory W. Barsness, David R. 
Holmes, Jr., Mayo Clinic, Rochester, MN 
Background: The influence of diabetic treatment status on long-term outcome after per- 
cutaneous coronary intervention (PCI) is unclear: previous reports suggest that insulin 
treatment is associated with worse long-term outcome compared to patients not requiring 
insulin. Whether this IS an independent effect of insulin treatment, or whether insulin is 
merely a marker of mole advanced atherosclerosis or other unknown variables is uncer- 
tain. 
Methods and Results: Patients with diabetes undergoing successful PCI from January I, 
1996, through June 30,2001, were divided into two groups based on whether or not they 
required insulin, excluding patients with shock or recent (< 7days) infarction. Cox propor- 
tional hazards models were utilized to estimate the association between diabetes treat- 
ment status and long-term survival. Eleven hundred and four eligible diabetic patients 
were identified and divided into those treated with insulin (418 patients) and those treated 
with either an oral agent or diet alone (666 patients). Insulin-treated pabents were less 
likely to be male, had more pr!or coronary revascularization. prior myocardial infarction, 
and congestive heart failure on presentation. Angiographic and procedural characteris- 
tics were comparable. Adjusting for differences in baseline characteristics, insulin treat- 
ment did not adversely effect long-term survival (odds ratio (OR) 1 .lO, 95% confidence 
intervals (Cl) 0.77-1.58). 
Conclusion: Among diabetic patients undergoing successful PCI, patients treated with 
insulin have worse long-term suwival. However, when adjusting for differences in base- 
line characteristics, insulin treatment was not independently associated with worse long- 
term survival, suggesting that the difference observed in the crude survival rates are due 
primarily to differences in demographic, clinical, and treatment characteristics. 
1197-193 Incidence, Management, and Outcomes of Coronary 
Perforation: An Analysis of 16,296 Patients 
James L. Orford Panayotis Fasseas, Carmelo J. Panetta, Ali E. Denktas, David R. 
Holmes, Peter B. Berger, Mayo Clinic, Rochester, MN 
Background: Coronary perforation is a feared complication of percutaneous coronary 
intervention (PCI). Methods and Results: We performed a retrospective analysis of 
16,296 patients (pts) in the Mayo Clinic PCI database (1990-2001) Identifying 95 pts with 
coronary perforation (0.56%, 95% Cl 0.46, 0.71). The incidence was highest with athero- 
ablative devices (laser, atherectomy) (1.16% 95% Cl 0.76, 1.64) compared with balloon 
angioplasty alone (0.42%. 95% Cl 0.29, 0.61) 01 coronary stenting (0.23%, 95% Cl 0.15, 
0.35; p<O.OOl). Management strategies included covered stents and cardiac surgery 
(table). Seven pts died (7.4%, 95% Cl 3.7, 14.5). Glycoprotein llbillla inhibitor use (n=33: 
34.7%) did not predict the incidence of tamponade (p=O.43) or death (p=O.64). Conclu- 
sions: Coronary perforation following laser and atherectomy is 2-4 times more common 
than after balloon angioplasty or stent placement, respectively; is associated with a sig- 
niflcant moltakty (7%), but usually does not require surgery or result in tamponade or 
death. 
Coronary Perforation According to Ellis Classification: Management and Clln~cal Outcames 
All Type I 
@=95) (W17) 
Treatment, n (%) 
Type II Type Ill Type lV 
(nG.9) (Il=lE) (n=2) 
Protamine 22 (23) 2 (12) 
Balloon inflation 63 (66) 9 (53) 
Covered stent 3 (3) 0 
Pericardiocentes 7 (7) 0 
is 
Surgery lO(11) 0 
Outcomes, n (%) 
6 (14) 11 (61) 1 (50) 
34 (59) 18 (100) t (50) 
0 3 (7) 0 
0 7 (39) 0 
5 (9) 5 (26) 0 
Tamponade 11 (12) 0 1 (2) 10 (56) 0 
Death 7 (7) f (6) 3 (5) 3(17) 0 
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1197-194 Clinical Outcome After Prehospital Thrombolysis 
Versus Percutaneous Coronary Intervention for ST 
Elevation Myocardial Infarction: Results of the START 
in Berlin Pilot Study 
Stefan Hoffmann, Richard Stern, lskander Atmowihardjo, Dietrich Andresen, Vivantes 
Klinikum am Urban, Berlin, Germany 
Purpose: Despite the accepted superiority of PCI over in hospital thrombolysis (TL), 
there are no data demonstrating a benefit for PCI when compared with prehospital (p)TL. 
Berlin has a well organized pTL program, prevwsly been proven as a feasible and safe 
approach for the treatment of AMI. START is a prospective, randomized study evaluating 
the clinical outcome after pTL compared with direct PCI. 
Methods: Patients (pts) with STEMI less than 6 hours, enrolled by MICU physicians, 
were randomly asigned to pTL with reteplase or PCI with stenting. Primary endpoint 
(CEP) is a composite of MACE during hospital stay (all-cause mortality or recurent Ml 01 
new/worsening CHF or disabling stroke. 
Results: From October 2000 to March 2002, 66 Pts were enrolled (44.pTL, 44.PCI). 
Median time delay from symptom onset (SO) to MICU arrival was 70 (45.125)min, from 
SO to first bolus of TL 85 (61.137)mln and from SO to first ballon 143 (1 IO-195)min. Pts. 
mean age was 60 (49-69) years, 78% were males and 5l%had an anterior Ml. There 
were no differences between the two groups regarding baseline characteristics. The CEP 
was similary for pTL and PCI (13,6% vs. 15.9%). One recurent Ml occured in the pTL 
group, one death and one stroke in the PCI group. Thje incidence of CHF was equally for 
both treatments (13,6%). The need for urgent PCI was significantly higher I” the pTL 
group (32% vs. 5%, p=O.OOl). 
Conclusion: PCI does not offer clinical benefit over TL, when the administratlon of th 
drug starts very early in the prehospital setting. HOwever, the 32% rate of urgent PCI 
after thrombolytic therapy should focus on the need of a complex management strategy 
for AMI patients (invasive centers). 
1197-l 95 Aqueous Oxygen Therapy for ST-Segment Elevation 
Myocardial Infarction: AMIHOT Trial Design and 
Preliminary Results 
Jack L. Martin, Simon Dixon, Shukri David, Catherine Pensyl, Barbara Lindsay, William 
O’Neill, Main Line Health System, Bryr. Mawr, PA, William Beaumont Hospital, Detroit, 
Ml 
Background: Although rapid coronary reperfusion in ST segment elevation myocardial 
infarctlon (STEMI) improves recovery of left ventricular function and reduces mortality, 
epicardial vessel patency does not insure full restoration of nutrient flow at the tissue 
level. Animal and Phase 1 human testing of the TherOx@ Aqueous Oxygen (AO) System 
(TherOx Inc., Irvine, California) suggests that 6ercutaneous coronary infusion of autolo- 
gous blood mixed with hyperoxemlc saline may help overcome the downstream barrier to 
oxygen delivery in ischemic zones and improve myocardial salvage following primary 
angioplasty and stenting for STEMI. 
Methods: A Phase 2 randomized trial in the US is designed to evaluate the efficacv of 
regional A0 therapy in STEMI. A sub selective catheter is positioned in the infarct artery 
which delivers A0 oeriusion for 90 minutes at 75 ml/minute. Baseline contrast echocar- 
diography performed following coronary stenting and before randomization to A0 ther- 
apy or control is repeated at 24 hours, and days 30 and 90. Resting SPECT myocardial 
perfusion scans are obtained day 14. Prespecified endpoints include regional wall motion 
scores, SPECT perfusion defects and ST segment resolution. 
Results: Twenty patients have been randomized. Nine of IO patients assigned to A0 
therapy completed the 90 minute Infusion wthout hemodynamic 01 electrophysiologic 
instability. One patient could not cooperate due to noncardiac factors and received only 
68 minutes of infusion. Repeat angiography following A0 therapy documented stability of 
the pertwon catheter and maintenance of TIMI 3 flow in all subjects. The majority of the 
planned 250 patients are anticipated to be enrolled by March 2003. 
Conclusion: Preliminary results suggest that regional hyperoxemic therapy appears to 
be safe and can be readily applied in institutions performing primary angioplasty for 
STEMI. Conclusions regarding the promise of this new mode of therapy to improve 
recovery of left ventricular function requires longer-term follow up. 
1197-196 Effect of a Novel Pharmacological Strategy to 
Counteract Shivering During Endovascular Cooling for 
Acute Myocardial Infarction 
Simon R. Dixon, Shannon K. Maydick, Michael W. Dae, John T. Fox, Daniel I. Sessler. 
William W. O’Neill, William Beaumont Hospital, Royal Oak, MI, University of California 
San Francisco, San Francisco, CA 
Background: Mild hypothermia significantly reduces infarct size in experimental models 
of acute myocardial infarction (AMI). However, hypothermia triggers shivering, which is 
metabolically stressful. increases blood pressure and head rate, and often prevents fur- 
ther core cooling. We examined the efficacy and safety of a combined pharmacological 
strategy to suppress shivering in awake patients during endovascular cooling. 
Methods: One hundred and thirteen patients with acute ST-segment elevation Ml (c6- 
hours from symptom-onset) underwent primary PCI with adjunctive cooling. Hypothermia 
was induced using the SetPointa Temperature Management System (Radiant Medical 
Inc.. Redwood City, CA) to a target core temperature of 33°C for 3 hours after repedu- 
sion. The SetPoint system uses an endovascular heat exchange catheter that is placed 
in the inferior vena cava via the femoral vein. Skin warming, oral buspirone and intrave- 
nous meperidine were used to suppress shivering. 
Results: Seventy-eight (69%) patients had no evidence of shivering during cooling at an 
average minimum core temperature of 33+1 0°C. The remaining 35 patients experienced 
mild episodic shivering. Twenty-seven patients (24%) required additional boluses of 
meperidine to achieve a minimum core temperature of 33+l.o”C; nine patients (6%) 
